Roche registers two Phase II trials of RO7568282 in Parkinson's and Alzheimer's disease

Roche filed two new clinical trial registrations this week for its investigational drug RO7568282, both listed as not yet recruiting.

• "TARBELA-PD" (NCT07781644) is a Phase II study of RO7568282 in early-stage Parkinson's disease, sponsored by Hoffmann-La Roche. The trial plans to enroll 474 participants and will test high and low doses of RO7568282 against placebo¹, with the primary outcome tracking time to a confirmed motor progression event from the randomization date, measured by the MDS-UPDRS Part III score¹, and an estimated start date of 2026-09-30.
• "TARBELA-AD" (NCT07781657) is a Phase II study of RO7568282 in early symptomatic Alzheimer's disease, also sponsored by Hoffmann-La Roche. The study aims to compare the effects of RO7568282 versus a placebo in people in the early stages of Alzheimer's disease², with an estimated enrollment of 450 participants² and a primary outcome of change from baseline to Week 72 in Clinical Dementia Rating, Sum of Boxes (CDR-SB)², with an estimated start date of 2026-10-31.